[ET Net News Agency, 16 July 2019] Citi Research initiated coverage on Hansoh
Pharmaceutical (03692) with a "buy" rating and a target price of HK$30.
The research house said Hansoh has established a strong business with (1) innovative and
first-to-market generic R&D; (2) focus on attractive therapeutic areas; and (3) an
effective sales platform.
Citi believes Hansoh is a sustainable leader in the sector with continuous fast growth
that should be supported by consolidation and new product launches.
It noted that Hansoh is among the top-ranked R&D firms in China with 14 Category 1.1
innovative drug candidates (six in Phase II clinical trial or later stage), 59
first-to-market generic candidates, and 39 generic drug candidates in the pipeline. The
company targets to launch 30 drug candidates between 2019 and 2020.
Citi projected revenues of Rmb15.1bn for 2021, implying a 2017-21 CAGR of 25.1%. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
15.160 -0.500 (-3.193%) Others
16/07/2019 15:23
[I-bank focus]Citi starts Hansoh Pharma (03692) at HK$30
| Remark: | Real time quote last updated: 19/04/2024 11:19 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |